Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO ... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALNY)

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

Business Wire 5 days ago

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Business Wire 9 days ago

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

Business Wire October 30, 2025

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Business Wire October 16, 2025

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

Business Wire October 1, 2025

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Business Wire September 28, 2025

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

PR Newswire September 18, 2025

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

Business Wire September 9, 2025

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

Business Wire September 8, 2025
View More News ››

Opinion & Analysis (NDAQ:ALNY)

Investing in biotech stocks is not for amateurs (CLDX) (NPSP)

Marc Lichtenfeld January 17, 2014
View More Opinion ››

Bullboard Posts (NDAQ:ALNY)

Alnylam (ALNY): A Promising Biotech Poised for Transformativ

http://beyondspx.com/2024/07/31/alnylam-alny-a-promising-biotech-poised-for-transformative-growth/
MikeTester - August 2, 2024

RNA Interference (RNAi) Drug Delivery Market Size 2022-27

According to IMARC Group’s latest report, titled “RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size...
edwardebreen15 - August 22, 2022

Next multibagger

https://stockhouse.com/news/press-releases/2019/01/31/patient-five-cancer-free-twelve-months-after-single-anti-cancer-treatment
goregil - February 14, 2019

Stepping up today

I am getting my feet wet in this as I believe it is on the threshold of some exciting developments with respect to 'RNA Interference...
prested - March 24, 2014

ALNY Short Squeeze

With the press release today, there's a squeeze happening with the ALNY short-sellers.  Volume has hit approximately 3.5...
jdfm - July 16, 2012

Bought last week

Alnylam announced last Tuesday that it has filed to sell 7.5 million shares of common stock at $10.75 a share, with the intent of...
sparticuss - February 27, 2012
View more Bullboard ››

Mirasol Resources Ltd.

Mirasol Resources Ltd.

Mirasol Resources Ltd. is a Canada-based mineral exploration company focused on quality copper, gold and silver discoveries ...
View More »